• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Royalty Pharma plc (RPRX)

Ordinary Shares
Sell: $27.65|Buy: $28.07|Change: 0.31 (-1.09%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Address

110 East 59th Street
New York
NY
GBR
10022

Telephone

+1 212 8830200

Website

https://www.royaltypharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Royalty Pharma PLC First Quarter Earnings Conference Call for 20252025-05-09T08:00:00
Royalty Pharma PLC First Quarter Earnings Results for 20252025-05-09T00:00:00
Royalty Pharma PLC Fourth Quarter Earnings Conference Call for 20242025-02-14T08:00:00
Royalty Pharma PLC Fourth Quarter Earnings Results for 20242025-02-14T00:00:00
Royalty Pharma PLC Annual Report for 20242025-02-14T00:00:00
Royalty Pharma PLC Third Quarter Earnings Conference Call for 20242024-11-08T08:00:00
Royalty Pharma PLC Third Quarter Earnings Results for 20242024-11-08T00:00:00
Royalty Pharma PLC Second Quarter Earnings Conference Call for 20242024-08-08T08:00:00
Royalty Pharma PLC Second Quarter Earnings Results for 20242024-08-08T00:00:00
Royalty Pharma PLC Annual General Meeting for 20242024-06-21T09:00:00
BofA Securities 2024 Healthcare Conference2024-05-15T06:00:00
RBC Capital Markets 2024 Global Healthcare Conference2024-05-14T09:00:00
Royalty Pharma PLC First Quarter Earnings Conference Call for 20242024-05-09T08:00:00
Royalty Pharma PLC First Quarter Earnings Result for 20242024-05-09T00:00:00

Previous key dates

NameKey Date
BofA Securities 2024 Healthcare Conference2024-05-15T06:00:00
RBC Capital Markets 2024 Global Healthcare Conference2024-05-14T09:00:00
Royalty Pharma PLC First Quarter Earnings Conference Call for 20242024-05-09T08:00:00
Royalty Pharma PLC First Quarter Earnings Result for 20242024-05-09T00:00:00
Royalty Pharma plc TD Cowen’s 44th Annual Health Care Conference2024-03-05T10:30:00
Royalty Pharma PLC Fourth Quarter Earnings Conference Call for 20232024-02-15T08:00:00
Royalty Pharma PLC Fourth Quarter Earnings Result for 20232024-02-15T00:00:00
Royalty Pharma PLC Annual Report for 20232024-02-15T00:00:00
Royalty Pharma PLC Third Quarter Earnings Conference Call for 20232023-11-08T08:00:00
Royalty Pharma PLC Third Quarter Earnings Result for 20232023-11-08T00:00:00
Royalty Pharma at Citi’s 18th Annual BioPharma Conference2023-09-06T11:20:00
Royalty Pharma PLC Second Quarter Earnings Conference Call for 20232023-08-08T08:00:00
Royalty Pharma PLC Second Quarter Earnings Result for 20232023-08-08T00:00:00
Royalty Pharma PLC Annual General Meeting for 20232023-06-22T09:00:00
Royalty Pharma at the BofA Securities 2023 Health Care Conference2023-05-10T14:20:00
Royalty Pharma PLC First Quarter Earnings Conference Call for 20232023-05-09T08:00:00
Royalty Pharma PLC First Quarter Earnings Result for 20232023-05-09T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.